New England Journal of Medicine reports on PMO-based therapeutic

On Wednesday, the New England Journal of Medicine published clinical data for AVI-7288, a PMO-plus antisense oligonucleotide, demonstrating the drug's safety.

The study detailed the results of multiple ascending doses of the drug in healthy adult volunteers and showed no clinical or toxilogical affects along with no dose-dependent adverse side effects. A maximum dose was not determined by the study, which was conducted by the New England Journal of Medicine along with the U.S. Army Medical Research Institute of Infectious Diseases.

The drug itself is designed to bind to viral messenger RNA and input its own nucleoprotein into the virus, thereby preventing further infection by stopping replication and assembly.

"Results described in this manuscript provide further confirmation that PMO-based antisense therapeutics can protect against a highly pathogenic virus in nonhuman primate disease models and, importantly, that the dose regimen that we predict to be efficacious in humans is not likely to compromise patient safety during treatment,” USAMRIID Science Director Sina Bavari said in a news release.

Organizations in this Story

New England Journal of Medicine

Want to get notified whenever we write about New England Journal of Medicine ?
Next time we write about New England Journal of Medicine, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.